ACTG Publications

Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328).Bosch, Ronald J ; Pollard, Richard B ; Landay, Alan ; Aga, Evgenia ; Fox, Lawrence ; Mitsuyasu, Ronald2010AIDS Res Ther7
Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects.Twigg Iii, Homer L ; Weiden, Michael ; Valentine, Fred ; Schnizlein-Bick, Carol T ; Bassett, Roland ; Zheng, Lu ; Wheat, Joseph ; Day, Richard B ; Rominger, Helen ; Collman, Ronald G ; Fox, Lawrence ; Brizz, Barbara ; Dragavon, Joan ; Coombs, Robert W ; Bucy, R Pat ; AIDS Clinical Trials Group Protocol 723 Team2008 Jan 1J Infect Dis1197
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.Jacobson, Jeffrey M ; Pat Bucy, R ; Spritzler, John ; Saag, Michael S ; Eron, Joseph J ; Coombs, Robert W ; Wang, Rui ; Fox, Lawrence ; Johnson, Victoria A ; Cu-Uvin, Susan ; Cohn, Susan E ; Mildvan, Donna ; O'Neill, Dorothy ; Janik, Jennifer ; Purdue, Lynette ; O'Connor, Deborah K ; Vita, Christine Di ; Frank, Ian ; National Institute of 2006 Sep 1J Infect Dis5194
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.Sereti, Irini ; Dunham, Richard M ; Spritzler, John ; Aga, Evgenia ; Proschan, Michael A ; Medvik, Kathy ; Battaglia, Catherine A ; Landay, Alan L ; Pahwa, Savita ; Fischl, Margaret A ; Asmuth, David M ; Tenorio, Allan R ; Altman, John D ; Fox, Lawrence ; Moir, Susan ; Malaspina, Angela ; Morre, Michel ; Buffet, Renaud ; Silvestri, Guido ;2009 Jun 18Blood25113
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.Wilkin, Timothy J ; Lalama, Christina M ; McKinnon, John ; Gandhi, Rajesh T ; Lin, Nina ; Landay, Alan ; Ribaudo, Heather ; Fox, Lawrence ; Currier, Judith S ; Mellors, John W ; Gulick, Roy ; Tenorio, Allan R2012 Aug 15J Infect Dis4206
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).Kilby, J Michael ; Bucy, R Pat ; Mildvan, Donna ; Fischl, Margaret ; Santana-Bagur, Jorge ; Lennox, Jeff ; Pilcher, Chris ; Zolopa, Andrew ; Lawrence, Jody ; Pollard, Richard B ; Habib, Raphaelle El ; Sahner, David ; Fox, Lawrence ; Aga, Evgenia ; Bosch, Ronald J ; Mitsuyasu, Ronald ; Adult AIDS Clinical Trials Group A5024 Protocol Team2006 Dec 15J Infect Dis12194
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.Gandhi, Rajesh T ; O'Neill, David ; Bosch, Ronald J ; Chan, Ellen S ; Bucy, R Pat ; Shopis, Janet ; Baglyos, Lynn ; Adams, Elizabeth ; Fox, Lawrence ; Purdue, Lynette ; Marshak, Ann ; Flynn, Theresa ; Masih, Reena ; Schock, Barbara ; Mildvan, Donna ; Schlesinger, Sarah J ; Marovich, Mary A ; Bhardwaj, Nina ; Jacobson, Jeffrey M ; AIDS Clin2009 Oct 9Vaccine4327
A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment.Bosch, Ronald J ; Pollard, Richard B ; Landay, Alan ; Aga, Evgenia ; Fox, Lawrence ; Mitsuyasu, Ronald ; AIDS Clinical Trials Group A5132 Team2011 JunJ Interferon Cytokine Res631
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.Cillo, Anthony R ; Hilldorfer, Benedict B ; Lalama, Christina M ; McKinnon, John E ; Coombs, Robert W ; Tenorio, Allan R ; Fox, Lawrence ; Gandhi, Rajesh T ; Ribaudo, Heather ; Currier, Judith S ; Gulick, Roy M ; Wilkin, Timothy J ; Mellors, John W2015 Oct 23AIDS1629